CF101

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Keratoconjunctivitis Sicca

Conditions

Keratoconjunctivitis Sicca

Trial Timeline

Jul 1, 2011 → Dec 1, 2013

NCT ID

NCT01235234

About CF101

CF101 is a phase 3 stage product being developed by Can Fite Biopharma for Keratoconjunctivitis Sicca. The current trial status is completed. This product is registered under clinical trial identifier NCT01235234. Target conditions include Keratoconjunctivitis Sicca.

What happened to similar drugs?

1 of 8 similar drugs in Keratoconjunctivitis Sicca were approved

Approved (1) Terminated (0) Active (7)

✅Cyclosporine A + DexamethasoneNovartisApproved

🔄FK506Astellas PharmaPhase 3

🔄FK506 + placeboAstellas PharmaPhase 3

🔄OTX-101 0.09%Sun PharmaceuticalPhase 3

🔄cyclosporine + vehicle of OTX-101Sun PharmaceuticalPhase 3

🔄INS365 Ophthalmic SolutionMerckPhase 3

🔄RebamipideNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01235234	Phase 3	Completed	Jul 1, 2011	Dec 1, 2013	Keratoconjunctivitis Sicca
NCT00280917	Phase 2	Completed	Jun 1, 2006	Apr 1, 2007	Rheumatoid Arthritis

Competing Products

15 competing products in Keratoconjunctivitis Sicca

See all competitors

Product	Company	Stage	Hype Score
FK506	Astellas Pharma	Phase 3	40
FK506 + placebo	Astellas Pharma	Phase 3	40
OTX-101 0.09%	Sun Pharmaceutical	Phase 3	40
OTX-101 0.05% + OTX-101 0.09% + Vehicle	Sun Pharmaceutical	Phase 2/3	38
cyclosporine + vehicle of OTX-101	Sun Pharmaceutical	Phase 3	40
INS365 Ophthalmic Solution	Merck	Phase 3	40
Pimecrolimus + Vehicle	Novartis	Phase 2	35
Cyclosporine A + Dexamethasone	Novartis	Approved	43
Rebamipide	Novartis	Phase 3	40
Rebamipide	Novartis	Phase 3	40
Tasocitinib + Tasocitinib + vehicle for Tasocitinib	Pfizer	Phase 2	27
Dupilumab	Regeneron Pharmaceuticals	Phase 2	31
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo	Rigel Pharmaceuticals	Phase 1	23
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo	Rigel Pharmaceuticals	Phase 2	29
CF101 + Placebo	Can Fite Biopharma	Phase 2	25